AureusIQ

AureusIQ delivers modular insights — compact, AI-powered tools like drug pricing risk tear sheets, health technology assessment (HTA) trackers, and scenario models that are reviewed for clarity and consistency to help investors and pharma leaders act quickly on complex, fast-moving market signals. We launched with a focus on the evolving Most Favored Nation (MFN) drug pricing policy landscape and are now expanding into broader coverage areas including AI-powered tools aimed at accelerating evidence synthesis and decision-making in complex regulatory environments. Our approach blends technical precision with strategic speed, enabling clients to act quickly and confidently across global market access challenges. Our clients include: 1) Institutional investors & Family Offices 2) Biopharma strategy teams 3) Policy and HEOR professionals. 4) Government organizations We adopt a trust-first philosophy in our AI strategy, prioritizing transparency, reliability, and ethical alignment in all LLM-driven initiatives. In parallel, we are actively pursuing a research validation track in collaboration with academic partners to rigorously evaluate the accuracy and explainability of large language model (LLM)-based pricing intelligence. This effort is designed to generate evidence-backed insights that support a forthcoming submission to ISPOR, advancing our commitment to methodological rigor and thought leadership in healthcare pricing analytics.